Trial Profile
A Phase II Study Of Thalidomide And CPT-11 (IRINOTECAN) Following Radiotherapy For Glioblastoma Multiforme.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2011
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Thalidomide (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 26 Oct 2011 Additional lead trial center identified as reported by ClinicalTrials.gov.
- 26 Oct 2011 Actual end date Feb 2008 added as reported by ClinicalTrials.gov.
- 26 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.